MK2206, a selective AKT inhibitor, modulates ovarian cancer cell line sensitivity to carboplatin plus paclitaxel

被引：0
|
作者：
Zgheib, N. Bou [1 ]
Marchion, D. [1 ]
Xiong, Y. [1 ]
Stickles, X. [1 ]
Judson, P. [1 ]
Hakam, A. [1 ]
Bosquet, J. Gonzalez [1 ]
Wenham, R. [1 ]
Apte, S. [1 ]
Lancaster, J. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [31] WHAT IS THE BEST SCHEDULE FOR PACLITAXEL plus CARBOPLATIN AS FIRST-LINE TREATMENT IN PRIMARY OVARIAN CANCER?
    Sehouli, J.
    Oskay-Oezcelik, G.
    Lichtenegger, W.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3628 - 3628
  • [32] Computational drug repositioning identifies Akt inhibitor MK2206 binding to EZH2 as enhancer of Tazmetostat efficacy in inhibition of triple negative breast cancer proliferation
    Thirumugam, Gowripriya
    Sarathy, Gautham
    Verma, Shiv
    Dhekne, Shivani
    Krishnaswamy, Balamurugan
    Gupta, Sanjay
    Ramaswamy, Bhuvaneswari
    Shankar, Eswar
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC).
    Mack, P. C.
    Farneth, N.
    Mahaffey, C.
    Lara, P.
    Gandara, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
    Blagden, S.
    Hamilton, A.
    Mileshkin, L.
    Hall, M.
    Meniawy, T.
    Wong, S.
    Anandra, S.
    Buck, M.
    McAleer, D.
    Reedy, B. A.
    Noble, R. B.
    Smith, D. A.
    Morris, S. R.
    Gabra, H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 7 - 7
  • [35] Phase Ib dose-escalation trial of the AKT inhibitor (AKTi) MK2206 in combination with paclitaxel (P) and trastuzumab (H) in patients (pts) with HER2-overexpressing (HER2+) cancer.
    Chien, Amy Jo
    Thach-Giao Truong
    Melisko, Michelle E.
    Moasser, Mark M.
    Kelley, Robin Katie
    Korn, Michael
    Ko, Andrew H.
    Pantoja, Norma
    Reinert, Anne
    Grabowsky, Jennifer A.
    Magbanua, Mark Jesus M.
    Rugo, Hope S.
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity
    Yap, T. A.
    Patnaik, A.
    Fearen, I.
    Olmos, D.
    Papadopoulos, K.
    Tunariu, N.
    Sullivan, D.
    Yan, L.
    De Bono, J. S.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Toxicity and compliance of first line carboplatin plus paclitaxel in elderly patients with ovarian cancer treated in a single center
    Aziz, M.
    Peschardt, K.
    Herrstedt, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S35 - S35
  • [38] Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer
    Gupta, Shilpa
    Munster, Pamela N.
    Hollebecque, Antoine
    Argues, Guillem
    Dajanl, Olav
    Chang, Jonathan D.
    Swift, Ann M.
    Tosolini, Alessandra
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Investigating the potential of estrogen-related receptor gamma (ERRg) in colorectal cancer and examining the therapeutic implications of DN200434 (ERRg inverse agonist) & MK2206 (Akt inhibitor)
    Gulwani, D.
    Upadhyay, P.
    Goel, R.
    Das, P.
    Singh, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S68 - S69
  • [40] The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
    Liu, Ruixin
    Liu, Dingxie
    Xing, Mingzhao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (02): : E173 - E182
12345